<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342509</url>
  </required_header>
  <id_info>
    <org_study_id>RUB 4780-13</org_study_id>
    <nct_id>NCT02342509</nct_id>
  </id_info>
  <brief_title>Automated Control of End-tidal Volatile Anesthetic Concentration</brief_title>
  <acronym>MIRCONTROL</acronym>
  <official_title>Automated Control of End-tidal Volatile Anesthetic Concentration Using the MIRUS System: A Comparison of Isoflurane, Sevoflurane and Desflurane in Anesthesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The new MIRUS system as well as the established AnaConDa system uses a reflector to conserve
      volatile anaesthetics (VA). Both systems act with commercially available ICU ventilators. In
      contrast to AnaConDa the MIRUS includes an automated control of end-tidal VA concentrations.
      In this study the investigators compared feasibility, costs and recovery times after
      anaesthesia with isoflurane (ISO), sevoflurane (SEVO) or desflurane (DES) in ventilated and
      spontaneously breathing patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was approved by the appropriate Institutional Review Board. After written informed
      consent 63 ASA I-III patients undergoing elective hip or knee replacement surgery under
      general anesthesia were included. Patients were randomly organized into 3 groups (20-22
      each). Anesthesia was induced with intravenous anaesthetics. After tracheal intubation MIRUS
      automatically adjusted the end-tidal VA concentration to 1.0 MAC. Patients were ventilated
      with the Puritan Bennett 840 ICU ventilator. After 1 h of anaesthesia with 1.0 MAC the
      ventilator mode was switched from SIMV V+ (totally controlled ventilation, &quot;passive patient&quot;,
      with a tidal volume of 8 ml/IBW) to proportional assist ventilation (PAV) with 50% support
      (&quot;active patient&quot;). At the end of surgery the MIRUS system was stopped (MAC set to 0.0) and
      recovery times were measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>volatile anaesthetics (VA) consumption</measure>
    <time_frame>duration of anesthesia: max. 3 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recovery times</measure>
    <time_frame>duration post anesthesia care: max. 8 h after anesthesia</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Delayed Recovery From Anesthesia</condition>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)</description>
    <arm_group_label>Desflurane</arm_group_label>
    <other_name>Suprane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane</intervention_name>
    <description>Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)</description>
    <arm_group_label>Isoflurane</arm_group_label>
    <other_name>Forene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signing of the informed consent document (patient or relatives).

          -  Patient age 18 years or older.

          -  ASA I-III

        Exclusion Criteria:

          -  ASA IV patients

          -  Epidural or spinal analgesia

          -  Allergy or known hypersensitivity to any of the study drugs

          -  Patients with known or suspected genetic susceptibility to malignant hyperthermia

          -  Previous participation in this trial

          -  Participation in another clinical trial within 4 weeks prior to selection.

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Weber, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruhr-Universtiy of Bochum, Germany</affiliation>
  </overall_official>
  <reference>
    <citation>Bomberg H, Glas M, Groesdonk VH, Bellgardt M, Schwarz J, Volk T, Meiser A. A novel device for target controlled administration and reflection of desflurane--the Mirus™. Anaesthesia. 2014 Nov;69(11):1241-50. doi: 10.1111/anae.12798. Epub 2014 Jul 9.</citation>
    <PMID>25040673</PMID>
  </reference>
  <reference>
    <citation>Meiser A, Sirtl C, Bellgardt M, Lohmann S, Garthoff A, Kaiser J, Hügler P, Laubenthal HJ. Desflurane compared with propofol for postoperative sedation in the intensive care unit. Br J Anaesth. 2003 Mar;90(3):273-80.</citation>
    <PMID>12594136</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>January 14, 2015</last_update_submitted>
  <last_update_submitted_qc>January 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Martin Bellgardt</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>et Control</keyword>
  <keyword>inhalational sedation</keyword>
  <keyword>conserve volatile anesthetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

